Latest data show survival benefit for Ganymed's IMAB362

By BC Staff | Jun 7, 2016 | 1:02 AM GMT

Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG (Mainz, Germany) plus chemotherapy led to longer overall survival (OS) and

Read the full 297 word article

How to gain access

Continue reading with a
two-week free trial.